Table 3 Characteristics and median survival of patients in high and low expression groups
From: ADAR expression and copy number variation in patients with advanced gastric cancer
Characteristics | Median survival (months) | Log-rank P | |
|---|---|---|---|
High expression | Low expression | ||
Gender | |||
Male (n = 544) | 20.3 | 32.1 | 1.6e-5 |
Female (n = 236) | 15.2 | 93.2 | 4.3e-7 |
Tumor stage | |||
Stage 1 (n = 67) | NAa | NA | – |
Stage 2 (n = 140) | 29 | 78.6 | 0.103 |
Stage 3 (n = 305) | 22.4 | 52.6 | 2e-4 |
Stage 4 (n = 148) | 17.5 | 15.93 | 0.148 |
Histology | |||
Well differentiated (n = 32) | 14.5 | 45.1 | 0.053 |
Moderately differentiated (n = 67) | 30.4 | 56.9 | 0.428 |
Poorly differentiated (n = 165) | 23.6 | 40 | 0.105 |
Lauren classification | |||
Intestinal (n = 320) | 25.9 | 99.4 | 3.1e-5 |
Diffuse (n = 241) | 27.8 | 40 | 0.038 |
Mixed (n = 32) | 57.2 | 20.9 | 0.041 |
Treatment | |||
Surgery (n = 380) | 45.8 | 85.6 | 0.217 |
5-Fluorouracil (n = 152) | 9.2 | 21.3 | 3.3e-6 |